{"id":36910,"date":"2026-01-23T11:45:11","date_gmt":"2026-01-23T16:45:11","guid":{"rendered":"https:\/\/nephcure.org\/?p=36910"},"modified":"2026-01-23T11:51:55","modified_gmt":"2026-01-23T16:51:55","slug":"update-on-fda-decision-about-sparsentan-for-fsgs-nephcure-town-hall","status":"publish","type":"post","link":"https:\/\/nephcure.org\/es\/update-on-fda-decision-about-sparsentan-for-fsgs-nephcure-town-hall\/","title":{"rendered":"Update on FDA Decision About Sparsentan for FSGS | NephCure Town Hall"},"content":{"rendered":"

<\/a><\/p>\n\n\n\n

<\/a><\/p>\n\n\n\n

<\/div>\n\n\n
\n
\n
\n
\n
\n
\n
\n\n
\"L\u00ednea<\/figure>\n\n\n\n

Haga clic para ver...<\/h2>\n\n\n\n

<\/p>\n\n\n\n

The U.S. Food and Drug Administration (FDA) has been reviewing an application for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The initial date for the FDA to make a decision on this drug was January 13, 2026. On that date, the FDA issued what is called a major amendment, which means the review process will take more time. NephCure’s virtual townhall answered key questions about this decision and what it means for the FSGS community.<\/p>\n\n\n\n

<\/div>\n\n\n\nVisita nuestra p\u00e1gina de Youtube<\/a>\n\n<\/div><\/div>\n\n
\n\n
\n